Organovo Holdings Inc (ONVO): Rega marang dodolan

Logo korporat perusahaan Organovo Holdings Inc (ONVO)

Growth in the value of Organovo Holdings, Inc. (ONVO) is expected due to the creation of 3D tissues for intestinal and liver therapy. The current price-to-sales ratio confirms this trend, where the value 28.70 captures the metric level. Business efficiency is supported by external cloud data management and logistics. The stability of R&D processes is ensured by the regular updating of bioprinters for precise cell positioning.

Organovo - Multiplikator P/S ONVO (periode 04.07.2022 - 24.04.2025)

Rincian metrik lan analitis perusahaan organovo.com (ONVO)

- rega saiki lan proyeksi nilai saham:
Analisis fundamental perusahaan:ONVO - Organovo Holdings
Barang utama Organovo Holdings, Inc.

The P/S ratio determines the market value of one dollar of annual revenue, allowing for an assessment of the premium paid for an asset relative to its actual sales. By analyzing the rolling P/S of Organovo Holdings, Inc. (ONVO), an investor can discern market expectations for the capitalization of Organovo Holdings, Inc. during the integration of 3D bioprinting platforms into the research cycles of global biopharmaceutical behemoths.

Pesaing Organovo Holdings, Inc.

Rasio rega marang pendapatan ASND (Ascendis Pharma AS)|Rasio rega marang pendapatan madrigalpharma.com MDGL|Corcept Therapeutics Corp (CORT) - Rega marang dodolan|RYTM - Rasio rega marang pendapatan|AKRO: Rasio rega marang pendapatan|MTSR: Multiplikator P/S|MLTX - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Crinetics Corp|NewAmsterdam Pharma Corp (NAMS) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan soleno.life (SLNO)|Kapitalisasi marang pendapatan Amicus Therapeutics FOLD|Rasio kapitalisasi pasar marang pendapatan 89bio Inc|Multiplikator P/S Agios Pharmaceuticals, Inc. AGIO|GPCR: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan MiMedx Corp MDXG|RZLT (Rezolute Corp) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan LXRX|MBX (MBX Biosciences) - Multiplikator P/S|Kapitalisasi marang pendapatan Altimmune Inc (ALT)|Kapitalisasi marang pendapatan AARD (Aardvark Therapeutics Corp)|Kapitalisasi marang pendapatan Sagimet SGMT|Multiplikator P/S BIOA (BioAge Labs)|Multiplikator P/S Biomea Fusion BMEA|QNCX: Kapitalisasi marang pendapatan|GUTS: Rasio rega marang pendapatan|vTv Therapeutics Inc (VTVT) - Rasio rega marang pendapatan|ATPC: Kapitalisasi marang volume dodolan|PLUR (pluri-biotech.com) - Multiplikator P/S|SYBX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S LPCN|Koefisien rega marang pendapatan Matinas BioPharma Holdings, Inc.|Rasio rega marang pendapatan Spruce Biosciences Inc. SPRB|GLTO - Kapitalisasi marang pendapatan|CTCX - Rasio rega marang pendapatan|LUMO - Multiplikator P/S|Radius Recycling (RDUS) - Rasio rega marang pendapatan